109 related articles for article (PubMed ID: 16478794)
1. MDR1 polymorphisms predict the response to etoposide-cisplatin combination chemotherapy in small cell lung cancer.
Sohn JW; Lee SY; Lee SJ; Kim EJ; Cha SI; Kim CH; Lee JT; Jung TH; Park JY
Jpn J Clin Oncol; 2006 Mar; 36(3):137-41. PubMed ID: 16478794
[TBL] [Abstract][Full Text] [Related]
2. MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer.
Pan JH; Han JX; Wu JM; Sheng LJ; Huang HN; Yu QZ
Respiration; 2008; 75(4):380-5. PubMed ID: 17851225
[TBL] [Abstract][Full Text] [Related]
3. MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to docetaxel-cisplatin chemotherapy in patients with non-small-cell lung cancer.
Pan JH; Han JX; Wu JM; Huang HN; Yu QZ; Sheng LJ
Respiration; 2009; 78(1):49-55. PubMed ID: 18812689
[TBL] [Abstract][Full Text] [Related]
4. Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients.
Chen S; Huo X; Lin Y; Ban H; Lin Y; Li W; Zhang B; Au WW; Xu X
Int J Hyg Environ Health; 2010 Mar; 213(2):140-5. PubMed ID: 20189873
[TBL] [Abstract][Full Text] [Related]
5. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene.
Johne A; Köpke K; Gerloff T; Mai I; Rietbrock S; Meisel C; Hoffmeyer S; Kerb R; Fromm MF; Brinkmann U; Eichelbaum M; Brockmöller J; Cascorbi I; Roots I
Clin Pharmacol Ther; 2002 Nov; 72(5):584-94. PubMed ID: 12426522
[TBL] [Abstract][Full Text] [Related]
6. [Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].
Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Sun Y; Xu BH; Lin DX
Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):972-5. PubMed ID: 16061005
[TBL] [Abstract][Full Text] [Related]
7. Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non-small cell lung cancer.
Kandioler D; Stamatis G; Eberhardt W; Kappel S; Zöchbauer-Müller S; Kührer I; Mittlböck M; Zwrtek R; Aigner C; Bichler C; Tichy V; Hudec M; Bachleitner T; End A; Müller MR; Roth E; Klepetko W
J Thorac Cardiovasc Surg; 2008 May; 135(5):1036-41. PubMed ID: 18455581
[TBL] [Abstract][Full Text] [Related]
8. MDR1 C3435T polymorphism in patients with breast cancer.
Turgut S; Yaren A; Kursunluoglu R; Turgut G
Arch Med Res; 2007 Jul; 38(5):539-44. PubMed ID: 17560460
[TBL] [Abstract][Full Text] [Related]
9. Relationship between chemotherapy response of small cell lung cancer and P-glycoprotein or multidrug resistance-related protein expression.
Hsia TC; Lin CC; Wang JJ; Ho ST; Kao A
Lung; 2002; 180(3):173-9. PubMed ID: 12177731
[TBL] [Abstract][Full Text] [Related]
10. Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer.
Booton R; Ward T; Heighway J; Taylor P; Power F; Ashcroft L; Morris J; Thatcher N
Cancer; 2006 Jun; 106(11):2421-7. PubMed ID: 16649224
[TBL] [Abstract][Full Text] [Related]
11. Multidrug resistance in small cell lung cancer: expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease.
Triller N; Korosec P; Kern I; Kosnik M; Debeljak A
Lung Cancer; 2006 Nov; 54(2):235-40. PubMed ID: 16934363
[TBL] [Abstract][Full Text] [Related]
12. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S
J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
[TBL] [Abstract][Full Text] [Related]
13. The clinical role of MDR1 gene expression in human lung cancer.
Oka M; Fukuda M; Sakamoto A; Takatani H; Fukuda M; Soda H; Kohno S
Anticancer Res; 1997; 17(1B):721-4. PubMed ID: 9066608
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
[TBL] [Abstract][Full Text] [Related]
15. Glutathione-S transferase-pi expression in non small cell lung cancer in the assessment of response to chemotherapy.
Unsal M; Akpolat I; Kandemir B
Saudi Med J; 2003 May; 24(5):493-8. PubMed ID: 12847624
[TBL] [Abstract][Full Text] [Related]
16. [Comparing cisplatin plus etoposide with combination of mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer patients].
Cok G; Göksel T; Soyer S; Atil H; Güzelant A; Aysan T
Tuberk Toraks; 2006; 54(2):161-7. PubMed ID: 16924573
[TBL] [Abstract][Full Text] [Related]
17. Comparison of cisplatin-paclitaxel combination versus cisplatin-etoposide in patients with small-cell lung cancer: a Phase III study.
Dimitroulis J; Rapti A; Stathopoulos GP; Rigatos S; Stathopoulos J; Koutantos J; Athanasiadis A; Tsikritsaki K; Karaindros D; Katis K; Antoniou D; Toumbis M; Giamboudakis P
Oncol Rep; 2008 Oct; 20(4):879-84. PubMed ID: 18813830
[TBL] [Abstract][Full Text] [Related]
18. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer.
Giachino DF; Ghio P; Regazzoni S; Mandrile G; Novello S; Selvaggi G; Gregori D; DeMarchi M; Scagliotti GV
Clin Cancer Res; 2007 May; 13(10):2876-81. PubMed ID: 17504986
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin plus etoposide chemotherapy followed by thoracic irradiation and paclitaxel plus cisplatin consolidation therapy for patients with limited stage small cell lung carcinoma.
Kakolyris S; Agelidou A; Androulakis N; Tsaroucha E; Kouroussis Ch; Agelidou M; Karvounis N; Veslemes M; Christophylakis Ch; Argyraki A; Geroyianni A; Georgoulias V
Lung Cancer; 2006 Jul; 53(1):59-65. PubMed ID: 16716447
[TBL] [Abstract][Full Text] [Related]
20. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer.
Eckardt JR; von Pawel J; Papai Z; Tomova A; Tzekova V; Crofts TE; Brannon S; Wissel P; Ross G
J Clin Oncol; 2006 May; 24(13):2044-51. PubMed ID: 16648504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]